Ting Zhang, Yong Liu, Xianshu Yang, Gary E Martin, Huifang Yao, Jackie Shang, Randal M Bugianesi, Kenneth P Ellsworth, Lisa M Sonatore, Peter Nizner, Edward C Sherer, Susan E Hill, Ian W Knemeyer, Wayne M Geissler, Peter J Dandliker, Roy Helmy, Harold B Wood
Journal of medicinal chemistry 2016 Mar 10A potent and selective Factor IXa (FIXa) inhibitor was subjected to a series of liver microsomal incubations, which generated a number of metabolites. Using automated ligand identification system-affinity selection (ALIS-AS) methodology, metabolites in the incubation mixture were prioritized by their binding affinities to the FIXa protein. Microgram quantities of the metabolites of interest were then isolated through microisolation analytical capabilities, and structurally characterized using MicroCryoProbe heteronuclear 2D NMR techniques. The isolated metabolites recovered from the NMR experiments were then submitted directly to an in vitro FIXa enzymatic assay. The order of the metabolites' binding affinity to the Factor IXa protein from the ALIS assay was completely consistent with the enzymatic assay results. This work showcases an innovative and efficient approach to uncover structure-activity relationships (SARs) and guide drug design via microisolation-structural characterization and ALIS capabilities.
Ting Zhang, Yong Liu, Xianshu Yang, Gary E Martin, Huifang Yao, Jackie Shang, Randal M Bugianesi, Kenneth P Ellsworth, Lisa M Sonatore, Peter Nizner, Edward C Sherer, Susan E Hill, Ian W Knemeyer, Wayne M Geissler, Peter J Dandliker, Roy Helmy, Harold B Wood. Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program. Journal of medicinal chemistry. 2016 Mar 10;59(5):1818-29
PMID: 26871940
View Full Text